Provided by Tiger Trade Technology Pte. Ltd.

Foghorn Therapeutics Inc.

6.87
-0.2000-2.83%
Post-market: 6.870.00000.00%19:30 EDT
Volume:402.92K
Turnover:2.80M
Market Cap:407.98M
PE:-7.05
High:7.35
Open:7.35
Low:6.57
Close:7.07
52wk High:7.61
52wk Low:3.27
Shares:59.39M
Float Shares:28.08M
Volume Ratio:0.78
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9742
EPS(LYR):-1.1800
ROE:-470.38%
ROA:-19.92%
PB:-5.03
PE(LYR):-5.82

Loading ...

Evercore ISI Reaffirms Their Buy Rating on Foghorn Therapeutics (FHTX)

TIPRANKS
·
Aug 10

Foghorn Therapeutics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Foghorn Therapeutics Reports Q2 Results and Pipeline Progress

TIPRANKS
·
Aug 06

Foghorn Therapeutics Q2 EPS $(0.10) Beats $(0.23) Estimate, Sales $16.072M Beat $5.995M Estimate

Benzinga Earnings
·
Aug 06

Foghorn Therapeutics Q2 FY26 Net Loss Narrows to $7.2 Million; Collaboration Revenue Rises to $16.1 Million

Reuters
·
Aug 06

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

THOMSON REUTERS
·
Aug 06

Foghorn Therapeutics Inc Expected to Post a Loss of 26 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Analysts’ Top Healthcare Picks: Lemaitre Vascular (LMAT), Foghorn Therapeutics (FHTX)

TIPRANKS
·
Jul 20

Foghorn Therapeutics Shareholders Elect Directors at Annual Meeting

Reuters
·
Jun 25

Foghorn Therapeutics to present at Goldman Sachs Global Healthcare Conference 2026

Reuters
·
Jun 05

Foghorn Therapeutics joins Stifel Virtual Targeted Oncology Forum lineup

Reuters
·
May 12

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

GlobeNewswire
·
May 12

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 08

Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
May 08

Foghorn Therapeutics Highlights Q1 Progress in Oncology Pipeline

TIPRANKS
·
May 07

Foghorn Therapeutics Q1 FY26 net loss widens to $19.9 million; revenue falls 45% to $3.3 million

Reuters
·
May 07

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

THOMSON REUTERS
·
May 07

Foghorn Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 30

Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR

TIPRANKS
·
Apr 22

Foghorn reports preclinical data for SMARCA2 inhibitor FHD-909 in mouse models

Reuters
·
Apr 22